Hillengass headlines podium presentation at 2024 Tandem Meetings in San Antonio
- Data updated on CARTITUDE-2 clinical trial for multiple myeloma
- Given earlier, ciltacabtagene autoleucel produced deep, durable responses
- Even after early relapse, high-risk patients experienced durable efficacy
BUFFALO, N.Y. — The Chief of Myeloma at Roswell Park Comprehensive Cancer Center will deliver the latest findings of the CARTITUDE-2 clinical trial at the 2024 Tandem Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), running Feb. 21-24 in San Antonio, Texas.
Jens Hillengass, MD, PhD, who also serves as Vice Chair for Research at Roswell Park, will present a podium talk highlighting updated data from the phase 2 trial (NCT04133636), which demonstrated that a single infusion of the CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel; brand name Carvykti) resulted in deep, durable responses in multiple myeloma patients whose disease had progressed less than a year after autologous stem cell transplant (ASCT) or who experienced relapse after receiving up to three lines of initial therapy.
Cilta-cel is a chimeric antigen receptor (CAR) T-cell therapy that engineers the patient’s own T cells to target the B-cell maturation antigen (BCMA), which is expressed on multiple myeloma cells but not on most other cells. The FDA approved cilta-cel in 2022 for treating patients with relapsed or refractory multiple myeloma who previously had received at least four lines of therapy.
The clinical trial, designed to evaluate the safety and efficacy of cilta-cel, opened in November 2019 with 169 multiple myeloma patients who were assigned to eight different cohorts with different characteristics. Dr. Hillengass will report the updated data, collected in April 2023, for 20 patients in Cohort A, who had received between one and three prior lines…
Read the full article here
